Register for our free email digests:
Division of Merck & Co. Inc.
Latest From Guangdong Techpool Bio-Pharma Co. Ltd.
Takeda’s recent revelation that it had set aside around $450m for a planned M&A transaction in an undisclosed emerging market has triggered speculation about where and how the company might spend its money. Might China be in the mix?
Takeda tantalizingly disclosed during its third quarter results that it has set aside funds for an acquisition worth around $450m in an undisclosed emerging market. What are the likely targets?
Balanced scorecards, big data, and platform strategies are among the new tools being employed by pharma companies ramping up compliance and lowering risks in China, where market access remains challenging and pricing pressures persistent. Such commercial model innovation should also improve physician interaction while providing new medical solutions, said executives at a recent RDPAC gathering in Beijing.
Takeda opened its Shanghai Development Center in 2012 to accelerate introducing new medicines to China. Center Head Benny Li discusses Takeda’s R&D strategy and shares his experience about working with China FDA.
- Therapeutic Areas
- Gynecological, Urological
- Neurology, Nervous System
- Organon Group
- Western Europe
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
- Contact Info
Phone: (31) 412661222
P.O. Box 20 Oss, 5342 CC
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.